A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors
Clinical trial NCT06462716 · UNKNOWN
Trial details
- NCT number
- NCT06462716
- Sponsor
- Chengdu Baiyu Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-25
- Primary completion
- 2024-12-31
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.